MONECO Advisors LLC Has $359,000 Stock Holdings in GSK plc (NYSE:GSK)

MONECO Advisors LLC lessened its position in GSK plc (NYSE:GSK) by 13.8% during the 4th quarter, Holdings Channel reports. The firm owned 10,622 shares of the pharmaceutical company’s stock after selling 1,696 shares during the quarter. MONECO Advisors LLC’s holdings in GSK were worth $359,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Sunbelt Securities Inc. raised its holdings in shares of GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after buying an additional 302 shares during the last quarter. Indiana Trust & Investment Management Co raised its holdings in shares of GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock valued at $25,000 after buying an additional 500 shares during the last quarter. Crews Bank & Trust bought a new position in shares of GSK in the fourth quarter valued at about $26,000. Concord Wealth Partners raised its holdings in shares of GSK by 231.8% in the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 547 shares during the last quarter. Finally, ST Germain D J Co. Inc. raised its holdings in shares of GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 522 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

GSK Stock Performance

Shares of GSK stock opened at $37.03 on Tuesday. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The stock has a market cap of $76.74 billion, a PE ratio of 23.29, a price-to-earnings-growth ratio of 1.12 and a beta of 0.64. The stock has a 50-day moving average of $34.67 and a 200-day moving average of $37.32. GSK plc has a one year low of $31.72 and a one year high of $45.92.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, sell-side analysts expect that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a $0.3932 dividend. The ex-dividend date is Friday, February 21st. This is a boost from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.25%. GSK’s dividend payout ratio is 98.74%.

Analysts Set New Price Targets

A number of research firms recently issued reports on GSK. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and cut their price target for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Morgan Stanley assumed coverage on GSK in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. Finally, Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Seven research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.